DNMT3A
ENSG00000119772
Target class
Epigenetic regulator
Chromosome
2
Approved drugs
2
Clinical candidates (approved and in development)
2
- Approved drugs
- 2
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- No
- Target name
- DNMT3A
- Gene name
- DNA methyltransferase 3 alpha
- Gene symbol
- DNMT3A
- Protein name
- DNA (cytosine-5)-methyltransferase 3A (Dnmt3a) (EC 2.1.1.37) (Cysteine methyltransferase DNMT3A) (EC 2.1.1.-) (DNA methyltransferase HsaIIIA) (DNA MTase HsaIIIA) (M.HsaIIIA)
- Gene biotype
- Protein coding
- Gene family
- PWWP domain containing|MicroRNA protein coding host genes|7BS C5-cytosine DNA/RNA methyltransferases|DNA/RNA methyltransferases
- Target class
- Epigenetic regulator
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 20.9
- Tissue specificity (Gini)
- 0.275
- Tissue specificity (tau)
- 0.614
- KEGG gene identifiers
- hsa:1788
- Protein interaction confidence
- 0.86967
- Protein interaction partners
- 97
- R-HSA-212300
- R-HSA-3214858
- R-HSA-4655427
- R-HSA-5334118
- R-HSA-9710421
- R-HSA-9845323
- End position
- 25342590
- Start position
- 25227855
- Chromosome
- 2
- Strand
- Reverse
- Nucleus . Chromosome . Cytoplasm . Note=Accumulates in the major satellite repeats at pericentric heterochromatin. .
- Nucleoplasm
- PubMed 12138111
- PubMed 12145218
- Tissue specificity (tau)
- 0.614137
- Expression inequality (Gini)
- 0.275111
Expression in transcripts per million
- Brain - Cerebellum
- 20.9
- Brain - Cerebellar Hemisphere
- 18.86
- Pituitary
- 18.82
- Ovary
- 18.28
- Cells - EBV-transformed lymphocytes
- 15.53
Expression in transcripts per million
- Brain - Cerebellum20.9
- Brain - Cerebellar Hemisphere18.86
- Pituitary18.82
- Ovary18.28
- Cells - EBV-transformed lymphocytes15.53
- Uterus13.55
- Spleen12.77
- Cervix - Endocervix12.72
- Colon - Sigmoid12.34
- Fallopian Tube12.05
- Thyroid11.38
- Cervix - Ectocervix11.35
- Esophagus - Gastroesophageal Junction10.25
- Adrenal Gland9.74
- Esophagus - Muscularis9.37
- Prostate9.36
- Small Intestine - Terminal Ileum9.11
- Nerve - Tibial9.1
- Artery - Aorta9.07
- Lung8.92
- Testis8.64
- Bladder8.44
- Brain - Nucleus accumbens (basal ganglia)8.22
- Kidney - Medulla8.18
- Colon - Transverse7.93
And 29 more, listed on the interactive page.
- GO:0000122
- GO:0006346
- GO:0031048
- GO:0044027
- GO:0000791
- GO:0005634
- GO:0005654
- GO:0005694
- GO:0005737
- GO:0016363
- GO:0000978
- GO:0003677
- GO:0003714
- GO:0003886
- GO:0005515
- GO:0042802
- GO:0045322
- GO:0061629
- GO:0106222
Related records
Trials (1,090)
- "InDACtion" vs "3+7" Induction in AML
- 10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1
- 5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome
- 5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates
- 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
- A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML
- A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)
- A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
- A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma
- A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome
- A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma
- A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma
- A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)
- A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies
- A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients
- A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
- A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia
Drugs (2)
- Azacitidine DNA (cytosine-5)-methyltransferase 3A inhibitor
- Decitabine DNA (cytosine-5)-methyltransferase 3A inhibitor